Breaking Down SG&A Expenses: Insmed Incorporated vs MannKind Corporation

Insmed vs. MannKind: A Decade of SG&A Expense Trends

__timestampInsmed IncorporatedMannKind Corporation
Wednesday, January 1, 20143107300079383000
Thursday, January 1, 201543216000108402000
Friday, January 1, 20165067900046928000
Sunday, January 1, 20177917100074959000
Monday, January 1, 201816821800079716000
Tuesday, January 1, 201921079600074669000
Wednesday, January 1, 202020361300059040000
Friday, January 1, 202123427300077417000
Saturday, January 1, 202226578400091473000
Sunday, January 1, 202334450100094314000
Loading chart...

In pursuit of knowledge

A Comparative Analysis of SG&A Expenses: Insmed vs. MannKind

In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. Over the past decade, Insmed Incorporated and MannKind Corporation have demonstrated distinct approaches to managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Insmed's SG&A expenses surged by over 1,000%, peaking at approximately $345 million in 2023. This reflects a strategic investment in growth and market expansion. In contrast, MannKind's expenses remained relatively stable, with a modest increase of around 19% over the same period, reaching nearly $94 million in 2023. This stability suggests a focus on cost control and efficiency. The divergence in these financial strategies highlights the varied paths companies can take in pursuit of success. As the industry evolves, monitoring these trends provides valuable insights into the operational priorities of leading pharmaceutical firms.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025